Evaluating deep learning-based melanoma classification using immunohistochemistry and routine histology: A three center study.

Journal: PloS one
Published Date:

Abstract

Pathologists routinely use immunohistochemical (IHC)-stained tissue slides against MelanA in addition to hematoxylin and eosin (H&E)-stained slides to improve their accuracy in diagnosing melanomas. The use of diagnostic Deep Learning (DL)-based support systems for automated examination of tissue morphology and cellular composition has been well studied in standard H&E-stained tissue slides. In contrast, there are few studies that analyze IHC slides using DL. Therefore, we investigated the separate and joint performance of ResNets trained on MelanA and corresponding H&E-stained slides. The MelanA classifier achieved an area under receiver operating characteristics curve (AUROC) of 0.82 and 0.74 on out of distribution (OOD)-datasets, similar to the H&E-based benchmark classification of 0.81 and 0.75, respectively. A combined classifier using MelanA and H&E achieved AUROCs of 0.85 and 0.81 on the OOD datasets. DL MelanA-based assistance systems show the same performance as the benchmark H&E classification and may be improved by multi stain classification to assist pathologists in their clinical routine.

Authors

  • Christoph Wies
    Digital Biomarkers for Oncology Group, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Lucas Schneider
    Digital Biomarkers for Oncology Group, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Sarah HaggenmĂĽller
    Digital Biomarkers for Oncology Group, National Center for Tumor Diseases (NCT), German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Tabea-Clara Bucher
    Digital Biomarkers for Oncology Group, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Sarah Hobelsberger
    Skin Cancer Center at the University Cancer Centre and National Center for Tumor Diseases Dresden, Department of Dermatology, University Hospital Carl Gustav Carus, Technische Universität, Dresden, Germany.
  • Markus V Heppt
    Department of Dermatology, University Hospital Erlangen, University of Erlangen, Erlangen, Germany.
  • Gerardo Ferrara
    Anatomic Pathology Unit, Macerata General Hospital, Macerata, Italy.
  • Eva I Krieghoff-Henning
    Digital Biomarkers for Oncology Group, National Center for Tumor Diseases, German Cancer Research Center, Heidelberg, Germany.
  • Titus J Brinker
    National Center for Tumor Diseases (NCT), German Cancer Research Center (DKFZ), Heidelberg, Germany.